0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Eptifibatide"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$3,545USDGBP
EUR$3,939USDGBP
From
EUR$3,850USDGBP
EUR$4,850USDGBP
Myocardial Infarction Market Report 2025 - Product Thumbnail Image

Myocardial Infarction Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
EUR$4,490USDGBP
EUR$236USDGBP
  • 7 Results (Page 1 of 1)
Loading Indicator

Eptifibatide is a cardiovascular drug used to treat acute coronary syndrome (ACS). It is a glycoprotein IIb/IIIa inhibitor, which works by blocking the action of platelets in the blood, preventing them from forming clots. It is administered intravenously and is usually used in combination with other drugs such as aspirin and heparin. Eptifibatide is used to reduce the risk of death, heart attack, and stroke in patients with ACS. It is also used to reduce the risk of recurrent ischemic events in patients with unstable angina or non-ST-segment elevation myocardial infarction. Eptifibatide is available in the market as a generic drug and is also sold under the brand names Integrilin and Reopro. It is manufactured by several pharmaceutical companies, including Merck, Pfizer, and Bristol-Myers Squibb. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more